Dr Reddy's Laboratories Ltd ADR
RDY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$57.00 | Lxtff | Rljrfzdvf |
Dr. Reddy's New Products Continue to Offset Price Erosion
Dr. Reddy’s reported strong third-quarter results driven by new product launches and currency tailwinds, outpacing price erosion across regions and upholding its narrow moat. We maintain our fair value estimate of $60 per share.